Brief: Mendus AB (Publ) Mendus Presents Positive Survival Data From Advance Ii Trial Evaluating Dcp-001 As A Maintenance Therapy In Aml

Mendus AB (publ)

12/12/2022 18:02

Dec 12 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * MENDUS PRESENTS POSITIVE SURVIVAL DATA FROM ADVANCE II
TRIAL
EVALUATING DCP-001 AS A MAINTENANCE THERAPY IN AML
    * LONGER-TERM FOLLOW UP CONFIRMS EXCELLENT SAFETY PROFILE OF
DCP-001, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED

Source text for Eikon:  ID:nGNX6KZRVq 
Further company coverage:  IMMUN.ST 
 ((Reuters.Briefs@thomsonreuters.com;))